Neuronetics, Inc.
A maker of non-invasive medical devices that treat mental health conditions, Neuronetics built the NeuroStar system, which uses focused magnetic pulses to stimulate areas of the brain involved in mood. Founded in 2003, it became the first company cleared by the FDA to use transcranial magnetic stimulation for depression that didn't respond to medication. The name blends "neuro" with "kinetics," hinting at its technology that applies moving magnetic fields to nudge underactive brain regions back into action.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Chernett Jorey | 13D/AActivist | 13.92% | 10.60M | Aug 24, 2026 |
| Point72 Asset Management, L.P. | 13GPassive | 5% | 3.82M | Aug 14, 2026 |
| Point72 Capital Advisors, Inc. | 13GPassive | 5% | 3.82M | Aug 14, 2026 |
| Steven A. Cohen | 13GPassive | 5% | 3.82M | Aug 14, 2026 |
| Parian Ultreia LP | 13GPassive | 7% | 4.84M | Mar 17, 2026 |
| MADRYN ASSET MANAGEMENT, LP | 13D/AActivist | 30.3% | 20.74M | Mar 4, 2026 |
| MADRYN HEALTH ADVISORS II, LP | 13D/AActivist | 27% | 18.48M | Mar 4, 2026 |
| MADRYN HEALTH ADVISORS GP II, LLC | 13D/AActivist | 27% | 18.48M | Mar 4, 2026 |
| MADRYN HEALTH PARTNERS II (CAYMAN MASTER), LP | 13D/AActivist | 24.9% | 17.04M | Mar 4, 2026 |
| MADRYN SELECT OPPORTUNITIES, LP | 13D/AActivist | 3.3% | 2.26M | Mar 4, 2026 |